Previous Close | 58.49 |
Open | 58.47 |
Bid | 58.68 x 200 |
Ask | 58.90 x 200 |
Day's Range | 56.82 - 58.96 |
52 Week Range | 19.83 - 94.75 |
Volume | |
Avg. Volume | 1,571,227 |
Market Cap | 7.088B |
Beta (5Y Monthly) | 0.90 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.45 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 82.93 |
Subscribe to Yahoo Finance Plus to view Fair Value for APLS
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mark Delong, Chief Business & Strategy Officer of Apellis Pharmaceuticals Inc (NASDAQ:APLS), has sold 9,913 shares of the company on March 18, 2024, according to a recent SEC filing.
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]